A randomized, double-blind, placebo managed, section III scientific demo evaluated the efficacy and security profile of adalimumab for a monotherapy in people with RA who experienced failed to respond to csDMARDs [191]. The final results confirmed the two statistically significant enhancement while in the sickness exercise and a superb safety https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/